

Applicants : Tove Ringerike et al.
Serial No. : 10/577,268
Filed : April 26, 2006
Page : 3 of 8 of August 29, 2011 Supplemental
Amendment

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-7. (Canceled)

8. (Currently Amended) An expression vector comprising a plasmid selected from the group consisting of: p1-5'IL1 β /d1EGFP-N1 (SEQ ID NO:~~43~~), p2-5'IL1 β /d1EGFP-N1 (SEQ ID NO:~~24~~), p3-5' IL1 β /d1EGFP-N1 (SEQ ID NO:~~35~~), p4-5'IL1 β /d1EGFP-N1 (SEQ ID NO:~~46~~), p1-5'3' IL1 β /d1EGFP-N1 (SEQ ID NO:~~57~~), p2-5'3'IL1 β /d1EGFP-N1 (SEQ ID NO:~~68~~), p3-5'3'IL1 β /d1EGFP-N1 (SEQ ID NO:~~79~~), p4-5'3'IL1 β /d1EGFP-N1 (SEQ ID NO:~~810~~), p1-5'IL2/EGFP-1 (SEQ ID NO:~~911~~), p1-5'IL2/d2EGFP-1 (SEQ ID NO:~~4012~~), p1-5'3'IL2/d2EGFP-1 (SEQ ID NO:~~413~~), p1-3'TNF α /d1EGFP-N1 (SEQ ID NO:~~4214~~), p2-3'TNF α /EGFP-F (SEQ ID NO:~~4315~~), p3-3'TNF α /EGFP-F (SEQ ID NO:~~4416~~), p1-5'TNF α /d1EGFP-N1 (SEQ ID NO:~~4517~~), p1-5'3'TNF α /d1EGFP-N1 (SEQ ID NO:~~4618~~), p1-3'IL4/d1EGFP-N1 (SEQ ID NO:~~4719~~), p2-3'IL4/EGFP-F (SEQ ID NO:~~4820~~), p3-3'IL4/EGFP-F (SEQ ID NO:~~4921~~), p4-3'IL4/CA-EGFP (SEQ ID NO:~~2022~~), p5-3'IL4/d1EGFP-N1 (SEQ ID NO:~~2123~~), p1-5'IL4/EGFP-1 (SEQ ID NO:~~2224~~), p1-5'IL4/d1EGFP-N1 (SEQ ID NO:~~2326~~), p2-5'IL4/EGFP-1 (SEQ ID NO:~~2425~~), p2-5'IL4/d1EGFP-N1 (SEQ ID NO:~~2527~~), p1-5'3'IL4/EGFP-1 (SEQ ID NO:~~2630~~), p1-5'3'IL4/d1EGFP-N1 (SEQ ID NO:~~2728~~), p2-5'3'IL4/d1EGFP-N1 (SEQ ID NO:~~2829~~), p1-5'INF γ /EGFP-1 (SEQ ID NO:~~2931~~), p1-5'INF γ /d2EGFP-1 (SEQ ID NO:~~3032~~), p1-5'3'INF γ /d2EGFP-1 (SEQ ID NO:~~3133~~), p1-5'IL10/EGFP-1 (SEQ ID NO:~~3237~~), p1-5'3'IL10/EGFP-1 (SEQ ID NO:~~3339~~), p2-5'IL10/d2EGFP-1 (SEQ ID NO:~~3438~~), and p2-5'3'IL10/d2EGFP-1 (SEQ ID NO:~~3540~~).

9-44. (Canceled)

Applicants : Tove Ringerike et al.
Serial No. : 10/577,268
Filed : April 26, 2006
Page : 4 of 8 of August 29, 2011 Supplemental
Amendment

45. (Currently Amended) The expression vector of claim 8, wherein the plasmid is selected from the group consisting of: p4-5'IL1 β /d1EGFP-N1 (SEQ ID NO:46), p1-5'IL2/d2EGFP-1 (SEQ ID NO:4012), p1-5'3'TNF α /d1EGFP-N1 (SEQ ID NO:4618), p2-5'IL4/d1EGFP-N1 (SEQ ID NO:2527), p1-5'INF γ /d2EGFP-1 (SEQ ID NO:3032), and p2-5'IL10/d2EGFP-1 (SEQ ID NO:3438).

46. (Currently Amended) A single-celled host transformed or transfected with [[a]] the expression vector according to claim 8.

47. (Previously Presented) The single-celled host according to claim 46, characterised in that it is selected from the group encompassing bacteria, yeast, mammalian cells, plant cells, insect cells, as well as eukaryotic cell lines.

48. (Previously Presented) The single-celled host according to claim 47, characterised in that it is an immortal mammalian cell line.

49. (Previously Presented) The single-celled host according to claim 47, characterised in that it is a cell line selected from the group consisting of T cell leukemia cells, thymoma, mast cells, macrophage-monocytes, fibroblasts and keratinocytes.

50. (Previously Presented) The single-celled host according to claim 47, characterised in that it is a cell line selected from the group consisting of: EL4, BW5147.3, C57.1, J774A.1, 3T3 L1, MC/9 and HEL-30.

Applicants : Tove Ringerike et al.
Serial No. : 10/577,268
Filed : April 26, 2006
Page : 5 of 8 of August 29, 2011 Supplemental
Amendment

51. (Previously Presented) The single-celled host according to claim 47, characterised in that it is a cell line selected from the group consisting of: C/p1-5'3'TNF α -dEGFP/2 (deposited in ECACC, Accession No. 3091202), EL/p1-5'IL2-dEGFP/6 (deposited in ECACC, Accession No. 3091204), EL/p2-5'IL4-dEGFP/2 (deposited in ECACC, Accession No. 3091205), EL/p1-5'IFN γ -dEGFP/3 (deposited in ECACC, Accession No. 3091206), EL/p2-5'IL10-dEGFP/5 (deposited in ECACC, Accession No. 3091207), and J/p4-5'IL1 β -dEGFP/4 (deposited in ECACC, Accession No. 3091208).

52. (Previously Presented) A method of obtaining characteristics of a tested substance, characterised in that

- a) the tested substance is put into contact with the single-celled host according to claim 46,
- b) a change in the level of expression of a green fluorescent protein caused by the tested substance is determined,
- c) the change in the level of expression described in (b) is accepted as a characteristic of the tested substance.

53. (Previously Presented) A collection of cell lines comprising the single celled host of claim 51 and a positive control cell line which constitutively expresses a green fluorescent protein.

54. (Currently Amended) The collection of cell lines of claim 53, wherein the positive control cell line is a cell line which has been transformed with a plasmid selected from the group consisting of: p1-~~3'~~3'GAPDH3'GAPDH/d1EGFP-N1 (SEQ ID NO:~~3634~~), p2-~~3'~~3'GAPDH3'GAPDH/EGFP-F (SEQ ID NO:~~3735~~), p3-3'GAPDH/EGFP-F (SEQ ID NO:~~3836~~), pCA-EGFP-F (SEQ ID NO:~~391~~), and pCA-d1EGFP (SEQ ID NO:~~402~~).

Applicants : Tove Ringerike et al.
Serial No. : 10/577,268
Filed : April 26, 2006
Page : 6 of 8 of August 29, 2011 Supplemental
Amendment

55. (Previously Presented) The collection of cell lines of claim 53, wherein the positive control cell line is a cell line selected from the group consisting of C/pCA-EGFP-F/2 (deposited in ECACC, Accession No. 3091201) and EL/pCA-dEGFP/9 (deposited in ECACC, Accession No. 3091203).

56. (Previously Presented) The collection of cell lines according to claim 53, wherein the positive control cell line is a bacterial cell line, a yeast cell line, a mammalian cell line, a plant cell line, or an insect cell line.

57. (Previously Presented) A collection of cell lines according to claim 53, characterized in that the positive control cell line is an immortal mammalian cell line.

58. (Previously Presented) A collection of cell lines according to claim 53, characterized in that in the positive control cell line a gene sequence encoding the green fluorescent protein is operationally bound to a regulatory sequence selected from the group consisting of: 3' UTR GAPDH, CMV promoter/enhancer, and actin promoter.